Kinetic Muscles

http://www.kineticmuscles.com/

James Koeneman (CEO)

Company Location
2103 East Cedar Street, #3
Tempe, AZ 85281

Contact Numbers
Tel: (480) 557-0448
Fax: (480) 557-0449

Contact
James Koeneman
Title: CEO and President
jkoeneman@kineticmuscles.com

Company Overview

KMI addresses the dichotomy in neurotherapy. Recent neuroscience research results show repetitive activities in brain injured patients result in remarkable improvement in function. However, healthcare economics have forced continuing reductions in therapy time prohibiting effective labor-intensive therapy. KMI products facilitate repetitive practice through cost-effective home therapy and improve quality of life.

Expertise

Number of Employees	4
PhD	1
MS	1
Other Degreed	2

Awards
1. Presenter of 2002 Arizona V.C. Conference
2. Presenter 2003 at AZTech Invest in Innovation
3. SBIR from NIH (2)
4. Medical Design Excellence Award
5. AZ FAST Grant
6. ASU Technopolis Launch Pad
7. 3yr Dev. Contract from NIH

Specific Scientists
1. James Koeneman, Ph.D.

Core Competencies



Products and Services

Patents ***Describe:*** KMI has filed for patent protection for our core products, technologies and methodologies.

Research ***What Research:*** Development of stroke therapy devices

Describe: KMI has developed a device for the wrist and fingers. It is developing devices for shoulder, elbow and lower extremity.

Clinical Studies

Which Studies: Treatment of stroke and TBI patients with KMI devices

Describe: KMI has completed two pilot studies of the use of its devices and has received an SBIR grant that will help support future studies. Grant applications have been submitted to NIH to extend the studies.

Business Outlook

Mission Statement

The goal of KMI is to become The Neuromuscular Rehabilitation Company. KMI products are innovative assistive devices that facilitate Repetitive Task Practice methods that improve extremity motor function of stroke patients. The training devices have capabilities that utilize current treatment modalities such as stretching to induce muscle tone, EMG biofeedback to assist in increasing muscle recruitment, and biofeedback to reduce muscle tone.

Commercialization Strategy

Obtain clinical and financial treatment results in support of our HCPCS reimbursement submission. In the meantime we will work directly with patients to assist in obtaining coverage using existing codes.

Problems

Funded by founders, friends and family to date, we lack resources to market our device or fully fund the clinical trials that support our reimbursement strategy.

Competition

Competitive devices tend to focus on specific modalities. The first device marketed to assist the therapist in stroke therapy was the Automove, a neurostimulator biofeedback device that causes contraction of muscles. Research on very sophisticated and expensive robotic devices has been supported at MIT, Stanford and UC Irvine/UCLA, but these are expensive and clinic based . Based on the research at MIT the company Interactive Motion Technologies, Inc. has a device under development.

Needs and Interests